view the recording here
Thank you for taking the time to view this webinar, we hope you find it informative.
RCPath CPD accredited
Co-presenters: Mark Wilcox, Massimo Sartelli, Anda Samson, Emily Lees
– – – – –
If you require a certificate of attendance, details of how to obtain will appear at the end of the webinar.
Please note that once you have completed your details on the form, the certificate will be generated so please be ready to download your certificate immediately. We would like to inform delegates that each time a certificate is generated, we will be notified with details.
If you have any problems creating or downloading your certificate please contact Esme Carruthers at firstname.lastname@example.org
The aim of this course is to provide an overview of some of the commonly identified infection issues that occur in patients with intra- abdominal infections (IAIs). This course will identify the risk factors of intra-abdominal infections before examining current guidelines and treatment options for patients. This will be rounded off by an in depth case study going through patient presentation, diagnosis, treatment and outcomes.
This will open the log in page in your default browser, all you will need to do is input an email and make a password, then you will be automatically redirected to the course.
If you have any issues with accessing the course, please contact navin@BSAC.org.uk.
Professor Mark Wilcox, Consultant / Head of Microbiology Research & Development, Leeds Teaching Hospitals NHS Trust
Mark has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), Clinical Director of Pathology (6 years) and Head of Microbiology (15 years) at LTHT.
Professor Wilcox is Chair of PHE’s Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), and is a member of the PHE’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. Since the pandemic, he is a member of UK Scientific Advisory Group on Emergencies (SAGE, COVID-19; and chairs one of its subgroups on Nosocomial Infection), and a co-chair of DHSC’s UK Technical Validation Group for COVID-19 tests. He is a member of the Medical Research Council’s Infections and Immunity Board, and the Scientific Advisory Board for the EU Innovative Medicines Initiative’s COMBACTE-NET consortium. From 2017, he was seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England. He was the Deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee up until 2018.
He is an expert advisor to the Department of Health in England on healthcare associated infections (HCAIs), UK NICE (C. difficile management and antimicrobial evaluations project), the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and CARB-X panel on novel antimicrobials, and the European Centre for Disease Control. He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of Clinical Infectious Diseases, Journal of Hospital Infection and Infectious Diseases in Clinical Practice. He has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents, 1998-2016.
Professor Wilcox heads a Healthcare Associated Infection research team at the University of Leeds (hhttps://medicinehealth.leeds.ac.uk/
faculty-/dir-record/research-groups/905/healthcare-associated-infection-research-group), comprising ~30 doctors, scientists and nurses; projects include multiple aspects of Clostridium difficile infection, diagnostics, antibiotic resistance and the gut microbiome, staphylococcal infection, and the clinical development of new antimicrobial agents. He has a track record of translational research (https://medicinehealth.leeds.ac.uk/
professor-mark-wilcox), including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for 15 clinical trials of new anti-infective drugs, 1999-2018, has carried out multiple NIHR portfolio studies on healthcare associated infection topics, and is currently supplying central laboratory services for several clinical trials of antimicrobial agents. He has authored >560 papers and published a number of books and chapters. He is co-editor of Antimicrobial Chemotherapy (5th/6th/7th Eds, 2007/12/15).
Emily Lees, Clinical Lecturer, Department of Paediatrics, University of Oxford
I am a Clinical Lecturer in Paediatrics at the University of Oxford and a Research Fellow at Fitzwilliam College, Cambridge. I am completing my Paediatric clinical training in the field of Infectious Diseases and Immunology, based in Oxford. I completed an Academic Clinical Fellowship at the University of Liverpool during my first 3 years of Paediatric training. Following this, I undertook a PhD looking at the interactions of Salmonellae with the human host, in the form of hiPSC-derived gut organoids and macrophages at the Wellcome Trust Sanger Institute / Fitzwilliam College from 2016-2019, and returned to Fitzwilliam as a Research fellow in 2021 to continue my research on this topic alongside my clinical training.
Massimo Sartelli, Consultant surgeon at Department of General and Emergency Surgery, Macerata Hospital, Italy
He is consultant surgeon at Department of General and Emergency Surgery, Macerata Hospital, Area Vasta 3, (Italy) – Coordinator of Scientific Activities – Member of the Hospital Infection Control Committee.
He has performed more than 3,500 operations of general and emergency surgery.
His scientific activity is documented by publications in international scientific journals. He is author/co-author of eight manuals of emergency surgery.
In the last years he has devoted his updating to the study of surgical infections and sepsis. He coordinated WSES Guidelines for Management of Intra-abdominal Infections, WSES Guidelines for Management of Skin and Soft Tissue Infections and WSES Guidelines for Management of Clostridium difficile Infection in Surgical Patients.
He designed and coordinated four multicenter prospective studies (CIAOW Study, CIAO Study, WISS Study and PIPAS Study) involving medical institutions worldwide defining epidemiological and management profiles of intra-abdominal infections worldwide.
In 2016 he designed AGORA Project. A global Alliance for Rational and appropriate use of antibiotics in managing intra-abdominal infections with the participation of clinicians from 79 countries worldwide.
He is deputy editor of the World Journal of Emergency Surgery (WJES) and member of the Board of Directors of the World Society of Emergency Surgery (WSES). He is member of the steering committee of the European Sepsis Alliance (ESA) and of the council of the Surgical Infection Society Europe (SIS-E).
He is founder and acting director of the Global Alliance for Infections in Surgery.